These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33134181)

  • 1. Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Zhi H; Feng M; Liu S; Na T; Zhang N; BiLiGe W
    Front Oncol; 2020; 10():591001. PubMed ID: 33134181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma.
    Gu L; Li H; Wang H; Ma X; Wang L; Chen L; Zhao W; Zhang Y; Zhang X
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):499-508. PubMed ID: 27844145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis.
    Zhang L; Wu B; Zha Z; Zhao H; Feng Y
    Cancer Manag Res; 2018; 10():1687-1703. PubMed ID: 29970967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Zhang N; Zhang H; Zhu D; JiRiGaLa ; Yu D; Wang C; WuYunBiLiGe ; Amin ; ZhiHong ; Yu H; Chen X; Wang M
    Int J Surg; 2020 Jul; 79():66-73. PubMed ID: 32417461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy.
    Cortese BD; Chelluri R; Xia L; Ostrowski DA; Roberson DS; Strother M; Ding JM; Schwartz L; Lee DJ; Guzzo TJ
    Am J Clin Exp Urol; 2022; 10(5):327-333. PubMed ID: 36313210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Xu Y; Zhang Y; Wang X; Kang J; Liu X
    BMC Cancer; 2019 Feb; 19(1):168. PubMed ID: 30795756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with sarcomatoid dedifferentiation: A PRISMA-compliant systematic review and meta-analysis.
    Shan L; Shao X; Gu L; Wu M; Lin P; Yu Z; Chen Q; Zhu D
    Front Surg; 2022; 9():922150. PubMed ID: 36338616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.
    Pal SK; Jones JO; Carmichael C; Saikia J; Hsu J; Liu X; Figlin RA; Twardowski P; Lau C
    Urol Oncol; 2013 Nov; 31(8):1826-31. PubMed ID: 22608544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis.
    Esagian SM; Ziogas IA; Kosmidis D; Hossain MD; Tannir NM; Msaouel P
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data.
    Janisch F; Kienapfel C; Fühner C; Klotzbücher T; Marks P; Hillemacher T; Meyer CP; Iwata T; Parizi MK; Sauter G; Fisch M; Shariat SF; Dahlem R; Rink M
    Front Surg; 2021; 8():763271. PubMed ID: 34869564
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
    Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
    PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Liu Y; Zhou L; Chen Y; Liao B; Ye D; Wang K; Li H
    BMC Urol; 2019 Jun; 19(1):49. PubMed ID: 31174518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
    Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of prognostic nutritional index in the management of pulmonary sarcomatoid carcinoma.
    Wang Y; Cao Y; Liu J
    Clin Sarcoma Res; 2020 Dec; 10(1):26. PubMed ID: 33372627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic nutritional index and prognosis in renal cell carcinoma: A systematic review and meta-analysis.
    Kim SI; Kim SJ; Kim SJ; Cho DS
    Urol Oncol; 2021 Oct; 39(10):623-630. PubMed ID: 34253447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
    Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
    Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
    de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
    Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes.
    Gu L; Ai Q; Cheng Q; Ma X; Wang B; Huang Q; Li X; Zhang P; Liu K; Zhao X; Li H; Zhang X
    Cancer Cell Int; 2020 Nov; 20(1):550. PubMed ID: 33292281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.